Globalstar vs State Street SPDR S&P Biotech ETF — how do they compare? Globalstar trades at $83.42 (market cap $10.78B), while State Street SPDR S&P Biotech ETF trades at $153.87 (market cap $10.11B). The key difference: Globalstar and State Street SPDR S&P Biotech ETF are close in size by market cap, and Globalstar is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globalstar for 21 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| GSAT | XBI | |
|---|---|---|
Market Cap | $10.78B | $10.11B |
Volume | 723,953 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $84.43 | $169.55 |
52-Week Low | $41.54 | $104.99 |
Typical Hold Time | 21 Days | 38 Days |
Enterprise Value | $10.79B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Trailing returns across standard periods
Globalstar provides satellite and terrestrial connectivity services, including voice, data, asset tracking, and private wireless solutions. It operates a low-Earth-orbit satellite network and holds licensed mid-band spectrum.
Read more on GSAT →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →